{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T21:28:10Z","timestamp":1771190890784,"version":"3.50.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T00:00:00Z","timestamp":1507507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0180261","type":"journal-article","created":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T13:36:17Z","timestamp":1507556177000},"page":"e0180261","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-3192","authenticated-orcid":true,"given":"Shelagh M.","family":"Szabo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishan","family":"Hirji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karissa M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Juarez-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,10,9]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.12968\/hmed.2013.74.11.612","article-title":"Classical Hodgkin&apos;s lymphoma: past, present and future perspectives","volume":"74","author":"TA Eyre","year":"2013","journal-title":"British Journal of Hospital Medicine (2005)"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.critrevonc.2012.07.002","article-title":"Hodgkin lymphoma","volume":"85","author":"PG Gobbi","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1185\/03007995.2015.1008131","article-title":"The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas","volume":"31","author":"AR Macalalad","year":"2015","journal-title":"Current Medical Research & Opinion"},{"issue":"16","key":"ref4","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","article-title":"How I treat relapsed and refractory Hodgkin lymphoma","volume":"117","author":"J Kuruvilla","year":"2011","journal-title":"Blood"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin&apos;s lymphoma","volume":"12","author":"NS Majhail","year":"2006","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2013.02.002","article-title":"Advanced and relapsed\/refractory Hodgkin lymphoma: what has been achieved during the last 50 years","volume":"50","author":"TP Vassilakopoulos","year":"2013","journal-title":"Seminars in hematology"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"AK Gopal","year":"2015","journal-title":"Blood"},{"key":"ref8","unstructured":"U.S. Food &amp; Drug Administration. ADCETRIS<sup>\u00ae<\/sup> (brentuximab vedotin) FDA Label. 2016."},{"issue":"9980","key":"ref9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin&apos;s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"CH Moskowitz","year":"2015","journal-title":"The Lancet"},{"key":"ref10","article-title":"Use of Brentuximab vedotin as salvage therapy pre\u2014allogeneic stem cell transplantation in relapsed\/refractory CD30 positive lympho\u2014proliferative disorders: a single centre experience","author":"H Mediwake","year":"2017","journal-title":"Internal Medicine Journal"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2119","article-title":"Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and\/or refractory Hodgkin&apos;s lymphoma","volume":"32","author":"S Garciaz","year":"2014","journal-title":"Hematological oncology"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3109\/10428194.2015.1030639","article-title":"Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma","volume":"56","author":"CA Yasenchak","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref13","article-title":"The incidence rate and economic burden of community-acquired pneumonia in a working-age population","author":"Jonah Broulette","year":"2013","journal-title":"The incidence rate and economic burden of community-acquired pneumonia in a working-age population"},{"key":"ref14","unstructured":"Truven Health Analytics. Multi-State Medicaid Database User Guide. 2011."},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1542\/peds.2015-0871","article-title":"Comparison of health care spending and utilization among children with Medicaid insurance","volume":"136","author":"DZ Kuo","year":"2015","journal-title":"Pediatrics"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.acap.2016.10.016","article-title":"Inhaled Corticosteroid Claims and Outpatient Visits After Hospitalization for Asthma Among Commercially Insured Children","volume":"17","author":"AL Andrews","year":"2017","journal-title":"Acad Pediatr"},{"key":"ref17","article-title":"Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer","author":"GS Calip","year":"2017","journal-title":"J Oncol Pract"},{"key":"ref18","article-title":"Impact of Insurance Provider on Overall Costs in Failed Back Surgery Syndrome: A Cost Study of 122,827 Patients","author":"AA Elsamadicy","year":"2017","journal-title":"Neuromodulation"},{"key":"ref19","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines): Hodgkin lymphoma.2013. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#hodgkin\" xlink:type=\"simple\">https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#hodgkin<\/ext-link>."},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clinthera.2016.12.010","article-title":"Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States","volume":"39","author":"J Lin","year":"2017","journal-title":"Clin Ther"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000209289","article-title":"Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma","volume":"219","author":"S Schneeweiss","year":"2009","journal-title":"Dermatology"},{"issue":"8","key":"ref22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10428190600573325","article-title":"Medical costs associated with non-Hodgkin&apos;s lymphoma in the United States during the first two years of treatment","volume":"47","author":"L Kutikova","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10120-015-0486-z","article-title":"Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data","volume":"19","author":"LM Hess","year":"2016","journal-title":"Gastric Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.critrevonc.2016.04.019","article-title":"Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma: An updated review of published data from the named patient program","volume":"104","author":"PL Zinzani","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.critrevonc.2015.03.011","article-title":"Experience of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma and relapsed\/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature","volume":"95","author":"PL Zinzani","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"R Chen","year":"2016","journal-title":"Blood"},{"key":"ref27","article-title":"Real-world treatment patterns in patients with Hodgkin lymphoma (HL) treated with brentuximab vedotin (BV) in the US","author":"C. Shao","year":"2016","journal-title":"American Society of Clinical Oncology"},{"key":"ref28","article-title":"The cost of relapse in Hodgkin lymphoma","author":"R.N. Hansen","year":"2014","journal-title":"American Society of Clinical Oncology"},{"key":"ref29","article-title":"Utilization patterns and resource use in relapse\/refractory Hodgkin lymphoma (rrHL) patients treated with brentuximab vedotin (BV)","author":"C Shao","year":"2016","journal-title":"American Society of Hematology"},{"key":"ref30","unstructured":"Szabo SM, Juarez-Garcia A, Johnston KM, Davis C, Connors JM. Lines of therapy and costs of care of classical Hodgkin lymphoma in the US. ISPOR; Boston, MA2017."},{"key":"ref31","first-page":"79","article-title":"Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma","volume":"7","author":"T Siddiqi","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"issue":"6","key":"ref32","first-page":"e208","article-title":"Real-world impact of comparative effectiveness research findings on clinical practice","volume":"20","author":"TB Gibson","year":"2014","journal-title":"Am J Manag Care"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/ijcp.12863","article-title":"Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a &quot;real-world&quot; observational study in the United States","volume":"70","author":"GY Lip","year":"2016","journal-title":"Int J Clin Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0180261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T07:19:46Z","timestamp":1540279186000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0180261"}},"subtitle":[],"editor":[{"given":"Graciela","family":"Andrei","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,9]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0180261","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,9]]}}}